Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.
Roche culled two more Phase II Covid-19 programs, as announced in the Swiss pharma giant’s first-quarter 2021 financial report.
BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.
Five years after the company’s portfolio bottomed out, Bristol-Myers Squibb markets three of the world’s six best-selling pharma brands.
W2O reported 2019 revenue increased by 26 percent to $223 million from $177 million in 2018 and improved operating profit.
Teva Pharmaceutical’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Teva Pharmaceutical Industries said a two-year restructuring enabled the world’s largest generic drugmaker to turn a corner, as the company reported slightly better than expected fourth-quarter 2019 results.
Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.
Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.
Swiss pharma giant Novartis is writing off the company’s program to develop a generic copy of GlaxoSmithKline’s blockbuster inhaler Advair.
